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Abstract
Tracking genetic variations from positive SARS-CoV-2 samples yields crucial information
about the number of variants circulating in an outbreak and the possible lines of transmis-
sion but sequencing every positive SARS-CoV-2 sample would be prohibitively costly for
population-scale test and trace operations. Genotyping is a rapid, high-throughput and low-
cost alternative for screening positive SARS-CoV-2 samples in many settings. We have
designed a SNP identification pipeline to identify genetic variation using sequenced SARS-
CoV-2 samples. Our pipeline identifies a minimal marker panel that can define distinct geno-
types. To evaluate the system, we developed a genotyping panel to detect variants-identi-
fied from SARS-CoV-2 sequences surveyed between March and May 2020 and tested this
on 50 stored qRT-PCR positive SARS-CoV-2 clinical samples that had been collected
across the South West of the UK in April 2020. The 50 samples split into 15 distinct geno-
types and there was a 61.9% probability that any two randomly chosen samples from our
set of 50 would have a distinct genotype. In a high throughput laboratory, qRT-PCR positive
samples pooled into 384-well plates could be screened with a marker panel at a cost of <
£1.50 per sample. Our results demonstrate the usefulness of a SNP genotyping panel to
provide a rapid, cost-effective, and reliable way to monitor SARS-CoV-2 variants circulating
in an outbreak. Our analysis pipeline is publicly available and will allow for marker panels to
be updated periodically as viral genotypes arise or disappear from circulation.
Introduction
In March 2020 the World Health Organisation characterised the global outbreak of COVID-
19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a pan-
demic [1]. A huge global effort followed to learn more about the virus, how it is transmitted
and the disease it causes, in order to prevent and control outbreaks and find effective treat-
ments and vaccines.
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Since the first SARS-CoV-2 genome sequence was released in January 2020, tens of thou-
sands of genome sequences have been shared online in public databases [2, 3]. Access to
sequence data is crucial for researchers to identify novel mutations, design diagnostic tests and
vaccines, and to track outbreaks; allowing researchers to follow the transmission of SARS-
CoV-2 both locally and globally.
As with all viruses, SARS-CoV-2 accumulates random mutations during replication. The
viral replication complex has proof reading activity which may at least partially explain the rel-
atively low rate of accumulated mutations [4]. SARS-CoV-2 accumulates mutations at about
half the rate reported for influenza virus that does not have a proof-reading mechanism and
likely has different structural constraints on its own proteins [5–7].
Following the emergence of SARS-CoV-2, distinct lineages have formed as viruses circulat-
ing in particular regions evolved and increased in frequency. Consortia were galvanised to
sequence a large number of positive SARS-CoV-2 samples to track both the evolution and geo-
graphic movements of the virus [2, 3, 8, 9] and a nomenclature for SARS-CoV-2 lineages was
suggested to enable clear communication between research groups [10].
Contact tracing procedures that utilise genomic tools have been shown to reduce the size
and duration of an outbreak [11]; these tools also yield detailed information about lines of
transmission. To date, SARS-CoV-2 lineages have been determined by sequencing positive
SARS-CoV-2 samples. While thorough, this approach is costly and only a small proportion of
positive samples have been assigned to a lineage. Our research aims to address this issue by
developing a high-throughput, low-cost genotyping panel to identify circulating SARS-CoV-2
variants as genotypes. Fig 1 shows how this technique could be incorporated into diagnostic
pathways. RNA from positive samples, from individuals with COVID-19, could be further
screened with a SARS-CoV-2 genotyping panel to identify variants, thereby providing valuable
genomic data to investigate outbreaks, potentially identifying transmission pathways linking
local and regional cases and helping to inform possible interventions. Notably, efficient meth-
ods for tracking transmission of certain lineages could be vital in situations where mutations
are associated with increased transmission, severity of disease or vaccine failure. We use the
term genotype here as opposed to lineage as our system is designed to separate samples from
Fig 1. How the SARS-CoV-2 genotyping panel can be used to identify circulating SARS-CoV-2 variants.
https://doi.org/10.1371/journal.pone.0243185.g001
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an outbreak into distinct groups rather than attempt to infer their phylogenetic relationships
with other samples.
We have validated this approach by genotyping positive clinical SARS-CoV-2 samples and
show that this is an efficient method for assessing circulating variants in an outbreak.
Materials and methods
Samples
Extracted RNA from the supernatants of cultured cells infected with the laboratory cultured
SARS-CoV-2 isolates GBR/Liverpool_strain/2020 and hCoV-19/England/02/2020 were used
to validate the test genotyping panel (Table 1). The hCoV-19/England/02/2020 stock con-
tained a mixture of the wild type (wt) virus and a variant with a 24 nt deletion in the spike
gene as previously described [12].
Clinical samples. RNA from 50 qRT-PCR positive SARS-CoV-2 samples (supplied by
Public Health England, PHE) as RNA extracted from nasopharyngeal swabs were screened
using the test genotyping panel.
RNA extraction
Viral RNA was extracted from cell culture supernatants using a QIAamp Viral RNA Mini Kit
(Qiagen) according to the manufacturer’s instructions.
PHE samples: Viral RNA was extracted using the silica guanidinium isothiocyanate binding
method [13] adapted for the ThermoFisher Kingfisher using paramagnetic silica particles
(Magnesil, Promega).
Genotyping panel design
The trimmed SARS-CoV-2 genome sequences and related metadata were downloaded from
the COVID-19 Genomics UK (COG-UK) consortium website (https://www.cogconsortium.
uk/data/). To check for changes in marker frequencies between May and September 2020,
both the 2020-05-08 dataset (14,277 sequences) and the updated 2020-09-03 dataset (40,640
sequences) were downloaded.
Marker selection. For SNP design, COG-UK consortium alignment data were pre-pro-
cessed to select positions in the viral genome which were polymorphic with a minor allele fre-
quency of> 0.001. After this step, sequenced accessions with identical genotypes across the
polymorphic loci were removed to further simplify downstream analysis. Where two samples
differed only at ambiguous base positions (no base pair called and thus recorded as ‘N’), they
were considered as identical and only one was retained. Markers were then prioritised as fol-
lows. The SNP with the highest minor allele frequency was chosen as the first marker (the logic
Table 1. Laboratory samples used to validate the SARS-CoV-2 test genotyping panel.
Sample name Source Type Sequenced Spike Phenotype Comparison to Wuhan-Hu-1 GenBank Acc:










wt spike sequence A6948C, G11083T, C21005T, C25452T,












C8782T, T18488C, T23605G, T28144C,
A29596G (nsp14: I150T, ORF 8: L84S, ORF 10:
I13M)
�Sample known to contain wild type and deleted spike sequences (BrisΔS).
https://doi.org/10.1371/journal.pone.0243185.t001
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being that this allele will split the samples best into two groups). In subsequent steps, all
remaining markers were evaluated to determine which one discriminated the maximum num-
ber of remaining unresolved sample pairs. The highest scoring SNP became marker 2 and the
process iterated until either i) all samples could be separated into distinct genotypes, ii) no
SNPs remained or iii) adding further SNPs did not result in the resolution of any additional
sample pairs. For the final set of maximally informative SNPs, flanking sequences of 50 bases
up and down-stream of the marker were extracted from the full sequence alignment (S1
Table). If polymorphisms were observed at a frequency greater than 0.5% in the flanking
sequences, they were recorded as IUPAC ambiguity codes, such that they could be avoided
when designing primers for the genotyping assay. The pipeline also utilised the corresponding
COG-UK metadata file to assign lineages and locations to the genotypes in our analysis output
files. The complete pipeline of PERL scripts along with links to example input data files is avail-
able from https://github.com/pr0kary0te/SARSmarkers.
Primer design. SNP coordinates and 50 bases of flanking sequence both up and down-
stream of it (S1 Table) were provided to 3CR Bioscience Ltd to design oligos compatible with
One Step PACE-RT™ chemistry [14]. For each of the markers in the test panel, two allele-spe-
cific forward primers and one common reverse primer were designed with a PACE-specific
tail (sequences available in S2 Table).
Genotyping
Genotyping was performed using the One Step PACE-RT™ (PCR Allele Competitive Exten-
sion) kit (3CR Bioscience) scaled for 1,536 plate format, the approach is described in Fig 2.
Each One Step PACE-RT™ SNP genotyping reaction was performed using 2.5 ng RNA,
0.005 μL One Step RT-enzyme, 0.5 μL One Step PACE-RT genotyping master mix (3CR Bio-
science) and 0.018 μL assay mix (12 μM of each forward primer, 30 μM reverse primer) in a
total volume of 1 μL. The combined reverse transcription and DNA amplification reaction was
performed using a Hydrocycler-16 (LGC Genomics, UK) under the following conditions:
50˚C for 10 minutes; 94˚C for 15 minutes; 10 cycles of 94˚C for 20s, 65–57˚C for 60s (dropping
0.8˚C per cycle); 35–40 cycles 94˚C for 20s, 57˚C for 60s. Fluorescence detection was per-
formed at room temperature using a BMG Pherastar1 scanner fitted with Fl 485/520, Fl 520/
560 and Fl 570/610 optic modules. Genotype calling was performed using the Kraken software
package version 11.5 (LGC Genomics). Fluorescent intensity was normalised for pipetting vol-
ume using the ROX standard contained within the PACE-RT master mix.
Data analysis
Data analysis was performed only on those samples for which 10 or more probes produced a
genotype call. Samples were grouped into identical genotypes with the script qc_genotype_-
data.pl, which was added to the GITHUB (https://github.com/pr0kary0te/SARSmarkers)
along with the SNP marker discovery pipeline.
Results
Minimal marker set
Up to week 18, the high-quality COG-UK sequence alignment comprised 14,277 sequences, as
indicated in the accompanying metadata file. We found 41 SNPs meeting our criteria of a min-
imum minor allele frequency of 0.1%. Of these, our pipeline identified 22 as sufficient to pro-
vide the maximum possible discrimination between samples in the COG-UK dataset. Three
SNPs were removed manually from this list as either their flanking sequences (for probe
PLOS ONE Detecting SARS-CoV-2 variants with SNP genotyping
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design) were overlapping or contained ambiguous bases (‘N’) close to the SNP of interest.
Prior to wet-lab marker validation, we found that these 19 SNPs were capable of delineating 59
distinct variants from the COG-UK sequence alignment (S3 Table). To test the discriminatory
power of the 19-marker set (hereafter, named the test set), random pairs of haplotypes for our
marker positions were sampled from the COG-UK sequence alignment without replacement.
We found that 89.1% of 6,202 random sample pairs were distinct at one of more marker posi-
tions. The flanking sequences for the 19 selected SNPs of the test set (S1 Table), were sent to
3CR Biosciences for probe design.
Synonymous and non-synonymous SNPs. All nineteen SNP markers in the test set target
SNPs located in coding sequences. With regard to the codons within the open reading frame
(ORF) of these genes, five of the SNPs were at position 1, six at position 2 and eight at position
3. Twelve of the SNPs were non-synonymous and would result in changes to the amino acid at
the given position (Table 2).
Evaluation of the test set. Initial evaluation of the test set was performed using the two
cell culture propagated SARS-CoV-2 isolates GBR/Liverpool_strain/2020 and hCoV-19/
Fig 2. PACE-RT™ genotyping. a) The RNA sample, which here contains two SNP variants, is reverse transcribed to produce single stranded DNA. b) The target region
is then amplified using two, allele specific primers which differ in their 3’ terminal base and 5’ tail, and a common reverse primer. As PCR proceeds, the tail sequences of
allele-specific forward primers become incorporated in the amplified fragments and their sequence complements are generated. c) Reporting cassettes, initially
quenched, bind to the appropriate tail sequence complement, become unquenched and produce a light signal (HEX (red), FAM (blue)). d) Fluorescence intensity is
measured and plotted to determine allele calls. A mixed signal (green) is seen as equal signal from both fluorochromes. Samples at the origin are the no-template
controls (black) and unamplified samples (pink).
https://doi.org/10.1371/journal.pone.0243185.g002
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England/02/2020. The two virus genomes vary at ten nucleotide positions (Table 1) but have
no differences in the wt spike gene sequences. However, in addition to the wt viral genome,
the hCoV-19/England/02/2020 virus stock was known to contain a variant genome that arose
during viral passage in tissue culture, which had a 24 nt in frame deletion in the spike gene
sequence (BrisΔS, Table 1). Genotypes were obtained for all 19 markers (Table 3).
Concordance between genotyping and sequencing. The two SARS-CoV-2 isolates GBR/
Liverpool_strain/2020 and hCoV-19/England/02/2020 had been sequenced, enabling a com-
parison with our genotyping data (Table 3). All genotyping results were concordant with the
sequence data. In two cases, it was possible to confirm SNPs (at nts 11083 and 28144) differen-
tiating the two wt SARS-CoV-2 isolates with both sequence and genotyping data. We also
compared these data with the available COG-UK sequences from the 2020-05-08 dataset (rep-
resenting PCR positives samples circulating March–May 2020). This showed that the majority
of genotype calls concord with the major allele found in the COG-UK database.
Genotyping clinical SARS-CoV-2 samples
To further evaluate the test set we genotyped 50 SARS-CoV-2 positive samples obtained from
PHE (samples collected from the South West of England). For 41 of the 50 samples, results
were obtained from at least 50% of the SNP markers in our panel; those that fell below this
threshold were excluded from further analysis (S4 Table). For 22 of the remaining 41 samples
results were obtained for all 19 markers and for a further 13 samples, results were obtained
from at least 15 of the 20 markers.
We found that 11 of the 19 markers were polymorphic among the 50 PHE samples and
could be used to assign them to 15 distinct groups (Fig 3 and S4 Table). To quantify the utility
Table 2. Alternative SNPs and their effect on protein coding.
Primer ID Gene Protein Position Alternative Codons Syn. / Non-syn. Alternative amino acids
Bris_SARS-CoV-2_313 ORF1a Nsp2 3 CTC CTT Syn Leucine ——
Bris_SARS-CoV-2_1059 ORF1a Nsp2 2 ACC ATC Syn Threonine ——
Bris_SARS-CoV-2_2416 ORF1a Nsp3 3 TAC TAT Syn Threonine ——
Bris_SARS-CoV-2_2558 ORF1a Nsp3 1 CCA TCA Non Proline Serine
Bris_SARS-CoV-2_2891 ORF1a Nsp3 1 GCA ACA Non Alanine Threonine
Bris_SARS-CoV-2_4002 ORF1a Nsp3 2 ACT ATT Non Threonine Isoleucine
Bris_SARS-CoV-2_11083 ORF1a Nsp5 3 TTT TTG Non Phenylalanine Leucine
Bris_SARS-CoV-2_14408 ORF1ab Nsp12 2 CTT CCT Non Leucine Proline
Bris_SARS-CoV-2_14805 ORF1ab Nsp12 3 TAC TAT Syn Tyrosine ——
Bris_SARS-CoV-2_17247 ORF1ab Nsp13 3 CGT CGC Syn Arginine ——
Bris_SARS-CoV-2_19839 ORF1ab Nsp15 3 AAC AAT Syn Asparagine ——
Bris_SARS-CoV-2_20268 ORF1ab Nsp15 3 TTA TTG Syn Leucine ——
Bris_SARS-CoV-2_20578 ORF1ab Nsp15 1 GTG TTG Non Valine Leucine
Bris_SARS-CoV-2_25350 S Spike 2 CCA CTA Non Proline Leucine
Bris_SARS-CoV-2_25429 ORF3a Ap3a 1 GTA TTA Non Valine Leucine
Bris_SARS-CoV-2_25563 ORF3a Ap3a 3 CAG CAT Non Glutamine Histidine
Bris_SARS-CoV-2_27046 M Matrix 2 ACG ATG Non Threonine Methionine
Bris_SARS-CoV-2_28144 ORF8 Ap8 2 TTA TCA Non Leucine Serine
Bris_SARS-CoV-2_28580 N Nucleoprotein 1 GAT TAT Non Aspartate Tyrosine
In the Alternative Codons columns, the codon with the predominant SNP in the COG-UK 2020-05-08 dataset is listed first. Position refers to the SNP position with
respect to the in-frame codon. Abbreviations: Nsp = non-structural protein; Ap = accessory protein; Non = non-synonymous, Syn = synonymous.
https://doi.org/10.1371/journal.pone.0243185.t002
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of our SNP panel in separating positive samples into distinct groups, we sampled random
pairs of the 50 genotyped samples 1000 times and found that they were separated by at least
one marker in 619 cases (61.9%).
Marker fail rate in PHE samples. The average fail rate by marker (that is, the marker pro-
duced no signal for some samples) was 19.4% ranging from 4% (marker Bris_SARS-CoV-
2_25429) to 32% (markers Bris_SARS-CoV-2_2558 and Bris_SARS-CoV-2_25350). The num-
ber of fails per sample ranged from 0% (22 of the samples) to 80% (2 of the samples); those
samples with fewer than 10 calls (9 in total) were removed from further analysis (S4 Table).
An evolving target
The Microreact website [8] shows how SARS-CoV-2 lineage frequencies have changed during
the outbreak and similarly the SNPs we targeted in our panel also changed in frequency over
time. To quantify the effect of alterations in SNP frequency over time on the discriminative
power of the 19 SNP panel, it was tested bioinformatically against random pairs of samples
drawn from week 19 through week 35 in the 2020-09-03 COG-UK data. The probability of the
original marker set discriminating a random pair of samples decreased from 89.1 to 77.6%.
There was, however, an anomaly in this analysis as our G/T SNP at position 11,083, recorded
as a variant in the 2020-05-08 COG-UK data and polymorphic in our genotyping results, is
reported as the non-IUPAC character “?” the 2020-09-03 COG alignment due to it exhibiting
homoplasy in phylogenetic reconstruction (Andrew Rambaut, personal communication). The
loss of data for this marker from the latest COG-UK alignment means we will have
Table 3. Comparison of genotyping and sequencing data obtained for the test set.
Probe ID wt Liverpool_strain BetaCoV/England mix Notes COG-UK
Genotype Sequence Genotype Sequence
Bris_SARS-CoV-2_313 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_1059 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_2416 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_2558 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_2891 G:G G G:G G Concord G/A
Bris_SARS-CoV-2_4002 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_11083 T:T T G:G G Separation G/T
Bris_SARS-CoV-2_14408 C:C C C:C C Concord T/C
Bris_SARS-CoV-2_14805 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_17247 T:T T T:T T Concord T/C
Bris_SARS-CoV-2_19839 T:T T T:T T Concord T/C
Bris_SARS-CoV-2_20268 A:A A A:A A Concord A/G
Bris_SARS-CoV-2_20578 G:G G G:G G Concord G/T
Bris_SARS-CoV-2_25350 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_25429 G:G G G:G G Concord G/T
Bris_SARS-CoV-2_25563 G:G G G:G G Concord G/T
Bris_SARS-CoV-2_27046 C:C C C:C C Concord C/T
Bris_SARS-CoV-2_28144 T:T T C:C C Separation T/C
Bris_SARS-CoV-2_28580 G:G G G:G G Concord G/T
Sequences “Concord” where the SARS-CoV-2 isolates GBR/Liverpool_strain/2020 and hCoV-19/England/02/2020 all share the same genotype and sequence. Separation
denotes genotyping call differences between the two isolates confirmed by sequencing. Alleles in the last column are those reported in the COG-UK database (from the
2020-05-08 dataset COG consortium https://www.cogconsortium.uk/data/ (14,277 sequences) with the major/minor alleles.
https://doi.org/10.1371/journal.pone.0243185.t003
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underestimated the discriminatory power of our panel on more recent samples. Nonetheless,
we re-ran the SNP marker discovery pipeline on the week 19–35 sequences and found that the
number of SNPs present at a frequency greater than 0.001 had increased from 41 to 97 (noting
that the SNP at 11,083 has been masked out of that alignment) and that 51 markers were now
required to discriminate all samples to the maximum amount possible. However, the majority
of variants were extremely rare, such that just the first 24 markers (S5 Table) were capable of
discriminating 95% of randomly selected sample pairs.
Discussion
Bioinformatic analysis of COG-UK sequence alignment data from May 2020 suggested that a
small number of PACE-RT genotyping assays could provide useful viral genotype identifica-
tion for UK SARS-CoV-2 positive samples. We developed a genotyping ‘test panel’ of 19 mark-
ers; initial evaluation of a set of two SARS-CoV-2 isolates (GBR/Liverpool_strain/2020 and
Fig 3. Genotyping calls for all samples. SNPs with a single allele call per sample are marked in dark blue (major allele) or orange (minor allele). Mixed calls are shown
in gold and missing data in light blue. Twelve out of 19 markers were polymorphic in our small test panel of PHE samples and cell lines (eleven out of 19 markers were
polymorphic in PHE samples) and eight samples had mixed calls for one or more markers.
https://doi.org/10.1371/journal.pone.0243185.g003
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hCoV-19/England/02/2020) showed that all of the markers designed produced distinct geno-
types with low failure rates and comparison with available sequencing data confirmed the
alleles identified in the test panel. These results were also the first demonstration of genotyping
directly from an RNA virus in a single step assay.
We went on to test our panel on 50 qRT-PCR positive SARS-CoV-2 samples, that were col-
lected across the UK in April 2020. Whilst a few of the PCR-positive samples we obtained
from PHE did not produce results, for the majority of our test marker panel all of the markers
themselves performed as expected, with missing data being attributable to low quality naso-
pharyngeal swabs samples rather than with any particular markers. Eight of the nineteen
markers were not polymorphic in the clinical samples we were able to obtain, which was not
unexpected given the small sample size. Whilst we have no reason to assume that these eight
markers are not capable of producing polymorphic calls, we were unable to obtain any further
samples to test this during our study. The 50 samples could be split into 15 distinct genotypes
based on the genotyping data obtained and there was a 61.9% probability that any two ran-
domly chosen samples from our set of 50 would have a distinct genotype. This is lower than
the predicted discriminatory power of the panel (89.1%) and can be explained by missing data
for some sample/marker combinations, resulting from us having access to very limited quanti-
ties of PCR-positive samples, which at the time proved to be in high demand locally for valida-
tion of qPCR assays. In a standard diagnostic laboratory workflow, more RNA would be
available following qPCR positive sample results and could be used in a genotyping screen to
identify variants.
Genotyping can detect mixed viral samples. We found that eight of the 50 PHE samples had
mixed calls, with B2, E2, D5, G4, G5, H5 mixed at one SNP and F1 and H2 both mixed for
two. We interpret this as possible evidence of infection by two genotypes, differing in at least
one or two SNPs respectively. The ability of PACE-RT genotyping to correctly cluster geno-
types improves as larger number of samples are processed, so it is possible that some mixed
calls would resolve to single-allele calls as more samples were added to this pilot-scale dataset.
A limitation of genotyping is the ascertainment bias of the probe design. Novel mutations
cannot be detected which relies on an existing sequencing effort such as that performed by the
COG-UK Consortium. As new mutations are discovered by traditional sequencing, the tools
made available in our software pipeline may be used to design a relevant probe set for the cur-
rent circulating viral population. This requires the removal of redundant probes and introduc-
tion of some novel probes; involving primer design and optimisation using samples previously
sequenced to obtain clear amplification of probes in a positive control and the absence of
amplification in a non-target negative control.
Markers in the panel were updated based on variant analysis of the 2020-09-03 release of
sequences from the COG-UK consortium to reflect the new variants circulating in the UK. We
found 91 SNPs with a frequency > 0.01 in the week 19–35 analysis, compared to 41 SNPs in
the data to week 18. The majority of the SNPs were rare, however, and we found that limiting
the marker set to the most informative 24 markers gave us slightly better discriminatory power
on the week 19–35 samples (95% of random pairs differentiated) than our original 19 marker
set designed from week 1–18 data (89% differentiated). SNPs will continue to arise and go
extinct, but our analysis suggests that a small and cost-effective panel of 20–24 markers will
continue to provide useful discriminatory power in many settings. Our SNP panel was
designed using sequence data from across the UK. It would be equally possible to use the global
data from www.gisaid.org to design a set of markers for global surveillance, or to focus on a
specific region of the UK for panel design if desired: input sequences would simply be pre-fil-
tered using the sample region from the COG metadata file. Like other screening and genomic
surveillance tools it is necessary to update and optimise the SARS-CoV-2 genotyping panel as
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the virus evolves. Bespoke variant specific genotyping panels could also be designed to track
specific variants of concern, for example the B1.1.7 or B1.351 variants and could provide a
rapid approach to monitor variants.
While sequence data may offer a greater depth of information, PACE-RT genotyping can
offer a rapid and low-cost solution to rapidly identify sample differences within a population.
A set of 20–24 markers may be screened against 192 samples for around £2.30 per sample and
savings are possible as sample numbers increase beyond this.
Genotyping is highly scalable and suited to a high throughput setting but does not require
bespoke equipment which makes it suitable as an additional screening method in diagnostic
testing facilities. The methods described here may be performed with only a thermocycler and
FRET-capable plate reader such as that found within RT-PCR instruments. To scale up, a
small laboratory equipped with a 1536-well plate thermocycler and fluorescent plate-reader
along with sample handling robotics and sample tracking LIMS such as KRAKEN should be
able to genotype several thousand positive samples per day with input from a single trained
operator. As the data may be exported simply in an excel spreadsheet format, complex data
analysis pipelines are not required to obtain the genotype scores.
Conclusion
To date, SARS-CoV-2 variants have been determined by sequencing positive samples with
only a small proportion of PCR samples assessed; as of 9th October 2020 there were 36,593,879
reported global cases of COVID-19 and 141,000 viral genomic sequences deposited on
GISAID [15]. Our results show that PACE-RT genotyping with a small panel of SNPs can add
useful genotype information to PCR-positive samples at a low cost. The fast turnaround of this
approach coupled with the ease with which it can be automated means that it has the potential
to provide additional detail for epidemiological studies. It is not, however a substitute for con-
tinued sequencing. Rather, the two approaches are complementary and genotyping panels will
need to be cross checked against sequence alignments at regular intervals to ensure that new
mutations are included and that loci which have become fixed or nearly so, are replaced. At
the time of writing, it is not possible to sequence every PCR positive sample in the UK and gen-
otyping has the potential to add genotype information to all positive results with minimal
investment in equipment for diagnostic testing laboratories at very low cost per sample. Test-
ing laboratories may also consider designing their own marker panels based on regional or
national datasets (the latter in our case) to maximise the fit between sample SNP frequencies
and the panel. Our primer design pipeline is freely available for this purpose. The advantage of
PACE-RT technology is that the SNP panel can be modified at low cost on a regular basis; in a
medium to high-throughput laboratory the cost of new primer sets would not be a significant
factor. The only real limitation of our approach is that it is not necessarily possible to assign
samples to a specific named lineage in the way that full sequence data allows. We have shown,
however that there is a high probability (61.9%) of being able to separate any two samples into
distinct genotypes using our marker panel, and in many settings this will be sufficient to iden-
tify or rule out transmission routes and thus inform public health policy to minimise the
spread of the virus. With the recent emergence of several variants of concern and potential
importance in the context of vaccine deployment, this approach could provide a useful tool for
epidemiological surveillance.
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